Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) FCF Margin (2016 - 2025)

Historic FCF Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 26.24%.

  • Corcept Therapeutics' FCF Margin fell 130200.0% to 26.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.01%, marking a year-over-year decrease of 6000.0%. This contributed to the annual value of 29.02% for FY2024, which is 27100.0% up from last year.
  • Per Corcept Therapeutics' latest filing, its FCF Margin stood at 26.24% for Q3 2025, which was down 130200.0% from 22.57% recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' FCF Margin peaked at 50.5% during Q3 2021, and registered a low of 3.2% during Q1 2025.
  • For the 5-year period, Corcept Therapeutics' FCF Margin averaged around 30.18%, with its median value being 32.37% (2022).
  • Per our database at Business Quant, Corcept Therapeutics' FCF Margin plummeted by -308500bps in 2022 and then surged by 284800bps in 2024.
  • Quarter analysis of 5 years shows Corcept Therapeutics' FCF Margin stood at 49.95% in 2021, then crashed by -35bps to 32.37% in 2022, then plummeted by -87bps to 4.35% in 2023, then skyrocketed by 655bps to 32.83% in 2024, then fell by -20bps to 26.24% in 2025.
  • Its FCF Margin was 26.24% in Q3 2025, compared to 22.57% in Q2 2025 and 3.2% in Q1 2025.